Drugs / SRP-9004
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06747273 | Jan → Jun 2025 | autosomal recessive limb-girdle muscular dystrophy type 2D | Sarepta Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01976091 | Feb 2015 → Mar 2019 | autosomal recessive limb-girdle muscular dystrophy type 2D | Sarepta Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-15 | Sarepta Therapeutics, Inc. | Regulatory Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs sarepta.com ↗
Following input from the U.S. Food and Drug Administration (FDA), Office of Therapeutic Products (OTP), Sarepta is cleared to proceed with dosing in Study SRP-9005-101 (COMPASS) in the U.S. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-15 | Sarepta Therapeutics, Inc. | Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs sarepta.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRP-9004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01976091 ↗ |
| Route | Other | “via isolated limb infusion (ILI) administration” NCT01976091 ↗ |
| Target | SGCA | “Phase I/IIA Gene Transfer Clinical Trial for LGMD2D (Alpha-Sarcoglycan Deficiency) Using scAAVrh74.tMCK.hSGCA” NCT01976091 ↗ |